Emerging atypical clinicopathological manifestations of immune-mediated necrotizing myopathy (IMNM)
- PMID: 40315785
- PMCID: PMC12103981
- DOI: 10.1016/j.nmd.2025.105363
Emerging atypical clinicopathological manifestations of immune-mediated necrotizing myopathy (IMNM)
Abstract
Immune-mediated necrotizing myopathy (IMNM) is an autoimmune myopathy typically characterized by a subacute-onset, rapidly progressive proximal predominant weakness, markedly elevated creatine kinase (CK) levels, and myopathological features of necrotic and regenerating fibers with minimal or no lymphocytic infiltration. IMNM can be associated with anti-HMGCR and anti-SRP antibodies. Expediting a diagnosis and beginning treatment with immunotherapy is important as early treatment can improve patient symptoms and outcomes. Notably, recent evidence has revealed several atypical clinical and histopathologic phenotypes of IMNM, which can make recognizing this treatable disease challenging. There are reports of seropositive IMNM patients exhibiting a chronic and slowly progressive course of weakness, resembling limb-girdle muscular dystrophy, as well as isolated dysphagia, prominent oculobulbar involvement, or facioscapulohumeral muscular dystrophy-like phenotype. Some patients may present in presymptomatic stages with asymptomatic hyperCKemia. Myopathological findings of IMNM have also expanded to encompass features including tubular aggregates, myofibrillar pathology, mitochondrial myopathy, excessive lipid cumulation, and megaconial pathology. The aim of this review is to highlight these unusual clinical and histopathologic presentations of IMNM, as recognizing these atypical features of IMNM is crucial to expedite diagnosis, initiate appropriate immunotherapies, and improving prognosis in this treatable myopathy.
Keywords: Atypical clinical and histopathologic presentations; HMGCR antibodies; Immune-mediated necrotizing myopathy; Necrotizing autoimmune myopathy; SRP antibodies.
Copyright © 2025 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest None.
Similar articles
-
Immune-mediated necrotizing myopathy: Unusual presentations of a treatable disease.Muscle Nerve. 2021 Dec;64(6):734-739. doi: 10.1002/mus.27435. Epub 2021 Oct 15. Muscle Nerve. 2021. PMID: 34617293
-
Immune-Mediated Necrotizing Myopathy.Curr Rheumatol Rep. 2018 Mar 26;20(4):21. doi: 10.1007/s11926-018-0732-6. Curr Rheumatol Rep. 2018. PMID: 29582188 Free PMC article. Review.
-
Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.Autoimmun Rev. 2022 Feb;21(2):102993. doi: 10.1016/j.autrev.2021.102993. Epub 2021 Nov 16. Autoimmun Rev. 2022. PMID: 34798316 Review.
-
Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins.Joint Bone Spine. 2014 Jan;81(1):79-82. doi: 10.1016/j.jbspin.2013.06.008. Epub 2013 Aug 13. Joint Bone Spine. 2014. PMID: 23953224
-
Pediatric Immune-Mediated Necrotizing Myopathy: A Single-Center Retrospective Cohort Study.Pediatr Neurol. 2025 Jun;167:33-41. doi: 10.1016/j.pediatrneurol.2025.03.002. Epub 2025 Mar 14. Pediatr Neurol. 2025. PMID: 40203548
References
-
- Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Immune-Mediated Necrotizing Myopathies Working G. 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord. 2018;28(1):87–99. - PubMed
-
- Kassardjian CD, Lennon VA, Alfugham NB, Mahler M, Milone M. Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy. JAMA Neurol. 2015;72(9):996–1003. - PubMed
-
- Smith B Skeletal muscle necrosis associated with cainoma. J Pathol. 1969;97(2):207–10. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials